Non-human animals having a humanized lymphocyte-activation gene 3
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAlexander O. Mujica, Elena Burova, Andrew J. Murphy
Life of this patent
Estimating the term…
Abstract
Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
Claims10
A mouse whose genome comprises a humanized Lymphocyte activation gene 3 (Lag-3) gene at an endogenous Lag-3 locus,
- wherein a humanized Lag-3 polypeptide is expressed from the humanized Lag-3 gene on the surface of activated T-lymphocytes in the mouse,
- wherein the humanized Lag-3 polypeptide comprises (i) the first two N-terminal immunoglobulin-like domains of a human LAG-3 polypeptide and (ii) the transmembrane and intracellular domains of an endogenous mouse Lag-3 polypeptide, and
- wherein the humanized Lag-3 gene is operably linked to the endogenous mouse Lag-3 promoter at the endogenous Lag-3 locus.
A method of making a mouse comprising
- modifying a mouse genome so that the modified genome comprises a humanized Lag-3 gene at an endogenous Lag-3 locus, thereby making the mouse,
- wherein a humanized Lag-3 polypeptide is expressed from the humanized Lag-3 gene on the surface of activated T-lymphocytes in the mouse, and
- wherein the humanized Lag-3 polypeptide comprises (i) the first two N-terminal immunoglobulin-like domains of a human LAG-3 polypeptide and (ii) the transmembrane and intracellular domains of an endogenous mouse Lag-3 polypeptide, and
- wherein the humanized Lag-3 gene is operably linked to the endogenous mouse Lag-3 promoter at the endogenous Lag-3 locus.
Dependencies are inferred from the claim text.